Terrance P. Coyne, EVP and CFO of Royalty Pharma plc ($RPRX), sold nearly $29.8 million worth of shares through 26 open market transactions over the past year. His most recent sale occurred on March 2, 2026. These sales rank him 483rd among 11,678 insiders by total value sold, well above the average of $8.6 million per insider and 6.4 transactions. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 1875 | $48.33 | 125,317.0000 | 564,455,000 | 1.47% | 0.00% |
| April 1, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 32916 | $48.33 | 125,317.0000 | 564,455,000 | 20.80% | 0.01% |
| March 23, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 32916 | $45.53 | 160,108.0000 | 564,455,000 | 17.05% | 0.01% |
| March 23, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 1875 | $45.53 | 160,108.0000 | 564,455,000 | 1.16% | 0.00% |
| March 2, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 1292 | $46.67 | 195,482.0000 | 564,455,000 | 0.66% | 0.00% |
| March 2, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 10429 | $47.01 | 194,899.0000 | 564,455,000 | 5.08% | 0.00% |
| March 2, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 22487 | $46.67 | 205,328.0000 | 564,455,000 | 9.87% | 0.00% |
| March 2, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 583 | $47.01 | 194,899.0000 | 564,455,000 | 0.30% | 0.00% |
| Feb. 23, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 1875 | $45.32 | 229,690.0000 | 564,455,000 | 0.81% | 0.00% |
| Feb. 23, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 32916 | $45.32 | 229,690.0000 | 564,455,000 | 12.53% | 0.01% |
| Feb. 11, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | A | Class A Ordinary Shares | 26626 | $0.00 | 264,481.0000 | 564,455,000 | 11.19% | 0.00% |
| Feb. 3, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 6195 | $42.84 | 238,942.0000 | 564,455,000 | 2.53% | 0.00% |
| Feb. 2, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 5843 | $42.08 | 245,137.0000 | 564,455,000 | 2.33% | 0.00% |
| Feb. 4, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 19076 | $43.29 | 237,855.0000 | 564,455,000 | 7.42% | 0.00% |
| Feb. 3, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 108759 | $42.84 | 256,931.0000 | 564,455,000 | 29.74% | 0.02% |
| Feb. 2, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 102581 | $42.08 | 365,690.0000 | 564,455,000 | 21.91% | 0.02% |
| Feb. 4, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 1087 | $43.29 | 237,855.0000 | 564,455,000 | 0.45% | 0.00% |
| Jan. 20, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 65832 | $39.35 | 481,396.0000 | 564,455,000 | 12.03% | 0.01% |
| Jan. 20, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 3750 | $39.35 | 481,396.0000 | 564,455,000 | 0.77% | 0.00% |
| Jan. 2, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 3750 | $38.42 | 550,978.0000 | 564,455,000 | 0.68% | 0.00% |
| Jan. 2, 2026 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 65832 | $38.42 | 550,978.0000 | 564,455,000 | 10.67% | 0.01% |
| Dec. 15, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 65832 | $38.36 | 620,560.0000 | 566,754,000 | 9.59% | 0.01% |
| Dec. 15, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 3750 | $38.36 | 620,560.0000 | 566,754,000 | 0.60% | 0.00% |
| Dec. 1, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 65832 | $39.87 | 690,142.0000 | 566,754,000 | 8.71% | 0.01% |
| Dec. 1, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 3750 | $39.87 | 690,142.0000 | 566,754,000 | 0.54% | 0.00% |
| Nov. 24, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 3126 | $38.67 | 760,348.0000 | 566,754,000 | 0.41% | 0.00% |
| Nov. 24, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 55146 | $38.67 | 770,410.0000 | 566,754,000 | 6.68% | 0.01% |
| Nov. 24, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 10686 | $37.96 | 759,724.0000 | 566,754,000 | 1.39% | 0.00% |
| Nov. 24, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 624 | $37.96 | 759,724.0000 | 566,754,000 | 0.08% | 0.00% |
| Nov. 17, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 65844 | $39.30 | 829,306.0000 | 566,754,000 | 7.36% | 0.01% |
| Nov. 17, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 3750 | $39.30 | 829,306.0000 | 566,754,000 | 0.45% | 0.00% |
| Nov. 5, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | A | Class A Ordinary Shares | 6168 | $0.00 | 898,900.0000 | 566,754,000 | 0.69% | 0.00% |
| Aug. 8, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | G | LP interests in RPI US Partners 2019, LP | 1000 | $0.00 | 644,818.0000 | 594,108,000 | 0.15% | 0.00% |
| Aug. 6, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | A | Class A Ordinary Shares | 3696 | $0.00 | 892,732.0000 | 594,108,000 | 0.42% | 0.00% |
| May 16, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | A | Class E Ordinary Shares | 1807277 | $0.00 | 1,807,277.0000 | 594,108,000 | 9999.99% | 0.30% |
| May 8, 2025 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | A | Class A Ordinary Shares | 48646 | $0.00 | 889,036.0000 | 594,108,000 | 5.79% | 0.01% |
| Aug. 12, 2024 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | G | ICAI Interests | 2000 | $0.00 | 349,350.0000 | 602,900,000 | 0.57% | 0.00% |
| Aug. 9, 2023 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 37500 | $30.72 | 877,890.0000 | 437,972,000 | 4.10% | 0.01% |
| Aug. 10, 2023 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 37500 | $30.75 | 840,390.0000 | 437,972,000 | 4.27% | 0.01% |
| Aug. 8, 2023 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | G | ICAI Interests | 1650 | $0.00 | 351,350.0000 | 437,972,000 | 0.47% | 0.00% |
| July 12, 2023 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 37500 | $31.07 | 952,890.0000 | 437,972,000 | 3.79% | 0.01% |
| July 13, 2023 | Royalty Pharma plc | $RPRX | Coyne Terrance P. | EVP & CFO | S | Class A Ordinary Shares | 37500 | $30.93 | 915,390.0000 | 437,972,000 | 3.94% | 0.01% |